Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Foundations of ART Management in Heavily Treatment–Experienced Patients
  • CME

Eric S. Daar, MD
Released: October 6, 2022

Clinical Studies of Newer Agents in Heavily Treatment–Experienced Patients: Ibalizumab

TMB-301/311 was the registrational trial for ibalizumab (a monoclonal antibody that functions as an attachment inhibitor) and included 40 highly treatment–experienced patients.15 Trials of new agents in treatment-experienced patients tend to be small because the goal is primarily to see if the agent has intrinsic activity and to gain safety information.

This was a single-arm open-label study. A total of 53% of the people had resistance to all drugs from ≥3 classes and 68% had integrase resistance. They were given a loading dose of ibalizumab after 7 days of follow-up on their failing regimen. The primary endpoint of the study was proportion of participants with a reduction in HIV-1 RNA ≥0.5 log10 copies/mL at Day 14, demonstrating the intrinsic potency of the regimen. The table in the slide demonstrates that 83% achieved that primary endpoint.

Patients then received an OBR with infusions of ibalizumab 800 mg every 2 weeks. At Weeks 48 and 96, approximately 55% to 60% had HIV-1 RNA <50 copies/mL.16-19 This is a high rate of virologic suppression in these people with high levels of resistance.

Ibalizumab is not an easy drug to take because it requires an IV infusion every 2 weeks. But for those who need a new drug in a new class, this is an important option.

The safety profile of ibalizumab among these 40 patients was quite good with minimal adverse events. A total of 5 patients discontinued ibalizumab.15,19 The increase in CD4+ cell count was reasonable.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings